ROCHE HLDGS AG (RHHBY)

32.61
OTC Markets
Prev Close 32.42
Day Low/High 32.28 / 32.63
52 Wk Low/High 26.30 / 32.72
Exchange OTC Markets
Shares Outstanding 702.56B
Market Cap 182.22B
Div & Yield N.A. (N.A)

Glancy Prongay & Murray LLP Commences Investigation On Behalf Of Roche Holding AG Investors

Glancy Prongay & Murray LLP ("GPM") is investigating potential claims on behalf of investors of Roche Holding AG ("Roche" or the "Company") (Other OTC: RHHBY) concerning the Company and its officers'...

Here's Why There Is a Sea of Red Across Global Stock Markets Tuesday

Here's Why There Is a Sea of Red Across Global Stock Markets Tuesday

European stocks fell firmly amid a global equity market pullback.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures decline and shares in Europe fall amid a weak U.S. dollar, rising political tensions in the Gulf region and electoral risks in the U.K.

Roche Plunges After a Key Breast Cancer Treatment Trial Disappoints

Roche Plunges After a Key Breast Cancer Treatment Trial Disappoints

Not a good session for Roche.

Global Investors Adjust to Rising Political Risks

Global Investors Adjust to Rising Political Risks

European stocks open lower Tuesday as global investors trim risky positions amid rising political tensions in the Gulf region and the ongoing turmoil in the White House.

COMPANY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Roche Holding AG To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Roche Holding AG ("Roche" or the "Company") (OTCQX:RHHBY).

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Roche Holding AG - RHHBY

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Roche Holding AG.

APHINITY Study Shows Genentech's Perjeta-Based Regimen Reduced The Risk Of Invasive Cancer Returning Compared To Herceptin And Chemotherapy In HER2-Positive Early Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and Frontier Science Foundation (FS) today announced the Phase III...

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.

Phase III Study Showed Genentech's Alecensa (Alectinib) Reduced The Risk Of Disease Progression Or Death By More Than Half Versus Crizotinib As First-Line Treatment In A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III ALEX study showed Alecensa ® (alectinib) significantly reduced the risk of disease worsening or death...

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.

FDA Approves Genentech's Actemra (Tocilizumab) For Giant Cell Arteritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

Genentech To Present New Data On Personalized Medicines And Cancer Immunotherapies At The 2017 American Society Of Clinical Oncology (ASCO) Annual Meeting

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data on 20 approved and investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual...

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday

European Stocks Drift Lower as Trump's Move to Fire FBI Director Comey Tapers Bulls

European Stocks Drift Lower as Trump's Move to Fire FBI Director Comey Tapers Bulls

European stocks drifted lower Wednesday as investors trim bets in the region amid multi-year highs after President Donald Trump fired his FBI Director James Comey.

Roche Tops the Swiss Market After First Quarter Sales Beat Expectations

Roche Tops the Swiss Market After First Quarter Sales Beat Expectations

Sales rose 4% and were 2% ahead of expectation on strong sales from core drugs and promising results from new treatments.

New Data At AAN Reinforce Clinical Benefit Of Genentech's OCREVUS (Ocrelizumab) For Relapsing And Primary Progressive Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programs will be presented during the 69th American Academy of...

What to Expect From European Pharmaceuticals' First Quarter Results

What to Expect From European Pharmaceuticals' First Quarter Results

New drug launches and late stage trials will be under the microscope as eight European pharmaceuticals companies report Q1 earnings starting next week.

Genentech To Present New Data At AAN Reinforcing Efficacy And Safety Of Newly FDA Approved OCREVUS (Ocrelizumab) In Two Types Of Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing forms of multiple sclerosis (RMS) and primary progressive MS (PPMS)...

FDA Grants Genentech's TECENTRIQ (Atezolizumab) Accelerated Approval As Initial Treatment For Certain People With Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Approves Genentech's Lucentis (Ranibizumab Injection) For Diabetic Retinopathy, The Leading Cause Of Blindness Among Working Age Adults In The United States

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech Announces Positive Interim Results For Emicizumab In Phase III Study Of Children With Hemophilia A

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced interim results from the Phase III HAVEN 2 study evaluating emicizumab prophylaxis in children less than 12 years of age with hemophilia A...

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

Protalix Cystic Fibrosis Drug Study Results Worsen Over Time

The Protalix medicine alidornase alfa is designed to help cystic fibrosis patients clear their lungs by making mucus thin and loose.

Phase III Study Shows Genentech's Alecensa® Was Superior To Crizotinib In A Specific Type Of Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the global, randomized Phase III ALEX study met its primary endpoint and showed that Alecensa ® (alectinib) as an initial...

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

Incyte Cancer Immunotherapy Drug Is Object of Desire for Two Big Pharma Rivals

The broad development plan across five different types of cancer widens Incyte's lead over other IDO inhibitors in clinical development.